Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
Clinical trial NCT02685020 · COMPLETED
Trial details
- NCT number
- NCT02685020
- Sponsor
- Janssen Vaccines & Prevention B.V.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-28
- Primary completion
- 2018-01-05
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.